A new weight-loss biotech launched with $410 million and three assets from China. Roche’s Chugai penned a deal to develop multi-payload antibody-drug conjugates. Analysts weighed in on whether Legend Biotech and BeiGene could become buyout targets in 2025. And more.
read moreIn a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients with presbyopia for up to eight hours. More: 10s for Tenpoint: Biotech preps for '26 market launch after phase 3 win for combo
read more
CR-discovered NXP800 shows promise in clinical trials More: New therapy hope for prostate cancer patients Source: News
read more
Groundbreaking approval provides new hope for patients in England and Wales More: NICE recommends olaparib for BRCA-mutated breast cancer treatment Source: News
read moreMendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken up the chief commercial officer position at Mendaera, positioning him to apply experience gained at companies including Intuitive Surgical to the
read moreWith an on-body delivery system (OBDS) to deliver its subcutaneous (SC) formulation of Sarclisa, Sanofi may be finding the edge it needs to compete with Johnson & Johnson’s Darzalex in multiple myeloma. Sanofi has taken a major step in the
read more© 1994 - 2026 B.M. Pharmaceuticals